Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Eli Lilly and CompanyU.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerCompanies: Eli Lilly and CompanyInluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free...
- Eli Lilly and CompanyLilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseasesCompanies: Eli Lilly and CompanyEli Lilly and Company Merida Biosciences Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile Acquisition strengthens Lilly's immunology capabilities and its opportunity t